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ABSTRACT:
Long noncoding RNAs (lncRNAs) are increasingly implicated in cancer biology, 
contributing to essential cancer cell functions such as proliferation, invasion, and 
metastasis. In prostate cancer, several lncRNAs have been nominated as critical actors 
in disease pathogenesis. Among these, expression of PCGEM1 and PRNCR1 has been 
identified as a possible component in disease progression through the coordination of 
androgen receptor (AR) signaling (Yang et al., Nature 2013, see ref. [1]). However, 
concerns regarding the robustness of these findings have been suggested. Here, 
we sought to evaluate whether PCGEM1 and PRNCR1 are associated with prostate 
cancer. Through a comprehensive analysis of RNA-sequencing data (RNA-seq), we find 
evidence that PCGEM1 but not PRNCR1 is associated with prostate cancer. We employ 
a large cohort of >230 high-risk prostate cancer patients with long-term outcomes 
data to show that, in contrast to prior reports, neither gene is associated with poor 
patient outcomes. We further observe no evidence that PCGEM1 nor PRNCR1 interact 
with AR, and neither gene is a component of AR signaling. Thus, we conclusively 
demonstrate that PCGEM1 and PRNCR1 are not prognostic lncRNAs in prostate cancer 
and we refute suggestions that these lncRNAs interact in AR signaling.
INTRODUCTION
Long noncoding RNAs (lncRNAs) have emerged 
as a critical element in cell biology, contributing to a 
wide variety of cellular behaviors and functions [2]. In 
cancer, lncRNAs have been the subject of much research 
during the past five years. Notably, lncRNAs are known 
to coordinate aggressive phenotypes of several common 
tumors, including breast cancer and prostate cancer [3, 4]. 
Large profiling studies have suggested that upwards of 
10,000 lncRNAs may exist in the human genome [5]; yet 
only a fraction of these entities have been characterized. 
Thus, the identity and function of lncRNAs in cancer 
remains largely unknown.
In prostate cancer, several lncRNAs, including 
PCA3 and PCAT-1, have been shown to be upregulated 
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in patients with cancer [6-9]. Recently, two lncRNAs, 
PCGEM1 and PRNCR1, have been suggested in prostate 
cancer to act as mediators of castration-resistance disease 
by binding, in a direct and sequential fashion, to the 
androgen receptor (AR), causing ligand-independent 
activation of its gene expression programs [1]. While 
PCGEM1 has been observed in prostate cancer previously 
[6, 10], PRNCR1 is a poorly characterized transcript, and 
we were concerned that PRNCR1 had been nominated by 
previous global profiling studies of prostate cancers [7, 
11-14]. 
We therefore sought to investigate PRNCR1 and 
PCGEM1 in prostate cancer. In specific, we sought to 
reproduce three core observations suggested by Yang et al 
published in Nature (see [1]) and include: 1) that PRNCR1 
and PCGEM1 are highly overexpressed in aggressive 
forms of prostate cancer, 2) that these two lncRNAs bind 
to AR under ligand-stimulated conditions, and 3) that the 
coordination of PRNCR1 and PCGEM1 interact with AR 
via specific post-translational modifications of the AR 
protein. Here, we report that none of these three findings 
is fully reproducible. 
First, we asked whether PCGEM1 and PRNCR1 
are highly overexpressed in aggressive prostate cancer, 
as suggested by others (see [1, 15]). Indeed, while some 
have argued that these lncRNAs are critical in castration-
resistant prostate cancer [1], there has been no study 
that evaluated the expression of these lncRNAs in tissue 
samples from human castrate-resistant prostate cancers 
(CRPC). To evaluate these lncRNAs in more detail, 
we first assessed their expression levels in 171 human 
prostatic tissues using RNA sequencing data aggregated 
from four independent studies of prostate cancer, including 
our own internal datasets [1, 12-14] (Fig. 1A). Whereas 
we found robust expression of PCGEM1 in a subset of 
prostate tissues (RPKM >1 in 82 samples; RPKM >10 
in 27 samples), we observed scant levels of PRNCR1 in 
all samples (RPKM >1 in only 3 samples; RPKM >10 
in 0 samples) (Supplementary Table 1). This does not 
lend confidence to PRNCR1 as a significant entity in this 
disease. For comparison, we used the prostate cancer 
lncRNA SChLAP1 as a positive control. We found extreme 
overexpression of SChLAP1 in samples from all datasets 
(RPKM >1 in 69 samples; RPKM >10 in 26 samples) 
(Supplementary Fig. 1). To rule out the possibility that 
PRNCR1 was a non-poly-adenylated RNA, we verified 
experimentally that PRNCR1 was observed in the poly-A 
fraction of RNA that was used to generate the RNA-seq 
data (Supplementary Fig. 2).
Given the low support for PRNCR1 in the RNA-seq 
data, we next confirmed these findings using quantitative 
PCR (qPCR) in a large set of prostate cancer tissues 
including 34 PCAs and 31 CRPC tumors as well as 18 
benign adjacent tissues. As shown in Fig. 1B, PCGEM1 
is upregulated in clinically localized cancer, confirming 
the known literature [6, 10]; however PRNCR1 expression 
does not demonstrate a convincing association with 
prostate cancer. We found a borderline decrease in 
PRNCR1 expression in metastatic castrate-resistant cancer 
(p = 0.047, Student’s t-test). We used PCAT1, EZH2, and 
SChLAP1 as control genes, all of which have elevated 
expression in prostate cancer metastases. Conversely, 
we used PCA3 as a control gene that is known to be 
upregulated in localized prostate cancer but not metastatic 
prostate cancer. Finally, while PCGEM1 is upregulated 
in cancer patients from matched tumor/benign samples, 
PRNCR1 does not convincingly exhibit this pattern of 
upregulation (Supplementary Fig. 3).
Next, an independent analysis of 235 high-
risk prostate cancer tissues demonstrated that neither 
PCGEM1 nor PRNCR1 is associated with aggressive 
prostate cancer, and neither lncRNA stratifies prostate 
cancer-specific mortality (Fig. 1C,D and Supplementary 
Tables 2,3). An analysis of intermediate endpoints such 
as biochemical recurrence and progression to metastatic 
disease demonstrated a trend for PCGEM1 and PRNCR1 
to be associated with less aggressive disease and favorable 
outcomes (Supplementary Fig. 4), which contradicts 
previous claims that these lncRNAs are involved in 
an aggressive patient clinical course [1, 15]. Using an 
independent validation cohort of tissues we verified 
that neither PCGEM1 nor PRNCR1 is associated with 
aggressive prostate cancer (Supplementary Table 2). 
By contrast, we have used these datasets to confirm the 
prognostic utility of the lncRNA SChLAP1 in prostate 
cancer, and high expression of SChLAP1 is a powerful 
predictor for poor patient survival (Fig. 1E) [4]. 
Next, we examined whether PCGEM1 and PRNCR1 
interacted with AR. We performed RNA-IP (RIP) assays 
using two independent AR antibodies, including the same 
antibody that was previously used to show an interaction 
between these lncRNAs and AR [1]. In accordance with 
the published literature, we performed a time-series of 
RIP experiments following AR stimulation, because prior 
data suggests that these lncRNAs bind AR from 1-2 hours 
after AR stimulation but not at 4 hours post-stimulation 
[1]. In our RIP experiments, we could not confirm that AR 
binds to PCGEM1 or PRNCR1 at either 1 hour or 4 hours 
post-stimulation with DHT (Fig. 1F and Supplementary 
Fig. 5). Similarly, in cells grown at steady-state, we used a 
second AR antibody and did not observe binding between 
AR and PCGEM1 or PRNCR1 (Supplementary Fig. 6). 
DHT-stimulated cells also demonstrated no induction in 
PCGEM1 or PRNCR1 expression (Supplementary Fig. 7). 
These results imply that PCGEM1 and PRNCR1 are not 
AR-interacting lncRNAs.
Finally, earlier data propose that PCGEM1 and 
PRNCR1 interact with AR via specific post-translational 
modifications (PTMs), specifically K349 methylation 
(K349Me) for PCGEM1 and K631/K634 acetylation 
(K631Ac/K634Ac) for PRNCR1 [1]. To search for these 
PTMs, we independently performed mass spectrometry for 
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Figure 1: PCGEM1 and PRNCR1 are not associated with prostate cancer progression and do not bind the androgen 
receptor. (A) Plot showing PCGEM1 (grey bars) and PRNCR1 (red circles) expression levels (Reads per Kilobase per Million Reads, or 
RPKM) across 171 samples from four RNA-Seq studies of prostate cancer: Michigan Center for Translational Pathology (MCTP, internal 
data and dbGAP, phs000443.v1.p1), Ren et al. [13] (EGA, ERP00550), Kannan et al. [14] (GEO, GSE22260), and Pflueger et al. [12] 
(dbGAP, phs000310.v1.p1). Inset box shows descriptive statistics for each study. (B) Quantitative PCR for PCGEM1 and PRNCR1 in a 
cohort of prostate cancer tissues, benign (n = 18), localized cancer (n =34), metastatic cancer (n = 31).  An asterisk (*) indicates p < 0.05. 
Two asterisks (**) indicate p < 0.01.  n.s. = non-significant.  P values were determined by a two-tailed Student’s t-test. Data for SChLAP1 
is obtained and re-analyzed from a prior publication (ref. [4]). (C) PCGEM1 expression does not predict for prostate cancer-specific 
mortality (PCSM). (D) PRNCR1 expression does not predict for PCSM. (E) High SChLAP1 expression is a powerful predictor of PCSM (p 
= 0.0022). Data in (E) is reproduced from a prior publication (ref. [4]). P values in (C-E) are determined using a log-rank test.  (F) RNA- 
immunoprecipitation (RIP) for AR following stimulation of LNCaP cells with 100nM DHT does not show binding of PRNCR1 or PCGEM1 
to AR. U1 binding to SNRNP70 is used as a positive control. PCAT-1, ANRIL, and MALAT1 serve as negative controls. Inset: Western blot 
confirmation of AR protein pull-down by the immunoprecipitation assays.  Error bars represent S.E.M.
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AR in the LNCaP cell line, achieving 95% coverage of all 
possible tryptic peptides. We were unable to confirm that 
these PTMs (K349Me, K631Ac, or K634Ac) are present 
on AR (Supplementary Fig. 8 and Supplementary Table 
4).  To examine this discrepancy further, we re-analyzed 
prior AR MS data (found in [1]). Although this MS dataset 
was obtained with a trypsin digestion to prepare samples 
for MS, we found no fully tryptic peptides supporting 
the nomination of K349Me, K631Ac, or K634Ac 
(Supplementary Fig. 8). In fact, in the MS data for these 
PTMs in ref. [1], almost all peptides harboring these 
PTMs are non-tryptic, which are generally considered to 
be analysis artifacts since true non-tryptic peptides are 
exceedingly rare following a trypsin digestion [16-18] 
(Supplementary Discussion). Non-tryptic peptides are 
also associated with a high false-discovery rate [19].  All 
peptides nominating the K349Me, K631Ac, or K634Ac 
PTMs in ref. [1] also had multiple additional PTMs that 
were nominated, indicating non-specificity. These included 
extraordinarily rare and unusual PTMs such as oxidated 
lysine and deamidated asparagine, which suggest technical 
artifacts given the negligible likelihood of multiple rare 
and unusual PTMs occurring on true non-trypic peptides. 
The statistical confidence for these non-tryptic peptides 
is <5%, whereas the corresponding fully tryptic peptides 
for these amino acid residues had statistical confidences 
>90%.
In summary, we have been unable to show a 
convincing role for PCGEM1 or PRNCR1 in aggressive 
prostate cancer or AR signaling. First, our data analysis 
of numerous human prostate cancer tissues from multiple 
independent laboratories indicates that neither PCGEM1 
nor PRNCR1 are associated with castration-resistant 
prostate cancer. Second, we were unable to verify that 
PCGEM1 and PRNCR1 bind to the androgen receptor. 
Lastly, we are unconvinced that the K349Me, K631Ac, 
or K634Ac AR PTMs represent a plausible mechanism 
for interaction between AR and PCGEM1 and PRNCR1. 
While our results challenge the notion that PCGEM1 and 
PRNCR1 play a causal role in prostate cancer, we regard 
lncRNAs as an emerging field of study in cancer [3, 6, 20, 
21] and we are encouraged by the interest in lncRNAs in 
prostate cancer.
METHODS
Prostate tissues were obtained from the radical 
prostatectomy series and Rapid Autopsy Program 
at the University of Michigan tissue core. All tissue 
samples were collected with informed consent under an 
Institutional Review Board (IRB) approved protocol at 
the University of Michigan.  Outcomes analyses were 
performed on a cohort of Mayo Clinic prostate cancer 
radical prostatectomy samples obtained under an IRB-
approved protocol as described previously. Cell lines 
were maintained according to standard conditions. For 
RIP experiments, cells were deprived of androgen for 
48 hours prior to stimulation with 100nM DHT. RIP 
experiments were performed as previously described [1, 
4]. Bioinformatics analyses utilized publicly available 
RNA-Seq data. Please see Supplementary Methods for 
details.
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